Eli Lilly and Co. recently released positive results from a Phase IIb clinical trial of its dual GIP and GLP-1 receptor agonist diabetes treatment, but analysts say the drug will not be marketed until 2023, giving Novo Nordisk time to develop a competing product.
Lilly says next-gen diabetes drug performing well in clinical trial
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.